key: cord-0914098-d9gngmxa
authors: Agur, Timna; Ben-Dor, Naomi; Goldman, Shira; Lichtenberg, Shelly; Herman-Edelstein, Michal; Yahav, Dafna; Rozen-Zvi, Benaya; Zingerman, Boris
title: Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospective cohort study
date: 2021-04-11
journal: Nephrol Dial Transplant
DOI: 10.1093/ndt/gfab155
sha: 9ea5a668a1459dc98d2d96698d7c2af64249fbde
doc_id: 914098
cord_uid: d9gngmxa

nan

Emerging data established end stage renal disease (ESRD) as one of the highest risk comorbidities for severe COVID-19, with short-term mortality above 20% 1, 2 . Based on both a large clinical trial and real-life data from Israel in the general populations, the effectiveness of mRNA-based BNT162b2 vaccine against SARS-CoV-2 was estimated at 95% 3, 4 . Nevertheless, dialysis patients present diminished immune response following immunization with various vaccines, and the efficacy of the available SARS-CoV-2 vaccine among this vulnerable group is unknown 5 . Therefore, we performed a prospective study, evaluating antibody response among hemodialysis and peritoneal dialysis (PD) patients 2-6 weeks after receiving the second dose of BNT162b2.

The study included hemodialysis and PD patients who were vaccinated with 2 doses of BNT162b2 vaccine, 21 days apart. Patients treated with current chemotherapy or immunosuppressive drugs, those who had only one vaccine dose, those who had been infected by COVID-19 before or those who were unable to give consent were excluded. To confirm sustained response, consenting participants were evaluated 2-6 weeks after receiving the second vaccine dose and were followed for up to 8 weeks. The study was approved by the ethics committee of RMC. Demographic data were collected by interview and medical records and blood samples for anti-spike (anti-S) SARS-CoV-2 antibodies were collected during the routine dialysis visits. SARS-CoV-2 IgG II Quant (Abbott©) assay was used for quantitative measurement of anti-spike IgG antibodies of SARS-CoV-2. A test was considered as positive if IgG was above 50 AU/m 6 . The primary outcome was the rate of seropositivity for anti-S antibodies. Univariate and multivariate linear regression analyses were performed to explore factors associated with higher log transformed antibody titer. The results are presented as change of log transformed antibody level per unit of explanatory variable (B).

Overall, 122 hemodialysis patients were included in the study (Fig. S-1 ). Patients' characteristics are detailed in Table 1 (Table S-1) .

Of the 23 PD patients, 22 (95.6%) were seropositive for anti-S IgG. The geometric mean of anti-S titer was 1515.14 AU/ml, median level was 1560 AU/mL (IQR 254.8-6423 AU/ml) and the mean log transformed antibody level was 3.18±0.83 logAU/ml. There was no significant difference between the mean antibody titer of PD and hemodialysis patients (p=0.58). Younger age (B 0.034 per year decrease, 95% CI 0.009-0.06, p=0.011) and serum albumin above 3.5 gr/dl (B 1.147, 95% CI 0.536-1.758, p<0.001) were associated with higher log transformed antibody titer in a univariate analysis. Due to the small PD cohort, multivariate analysis was not performed.

Only two major adverse events following any vaccine dose were reported among 145 cohort participants. Major adverse events included: one syncope event, one day following the 1 st vaccination dose (hemodialysis patient), and one pericarditis event two days following 2 nd vaccination dose (PD patient).

Seropositivity rates following BNT162b2 vaccination in both hemodialysis and PD patients were high and comparable to the seropositivity rates reported in healthy volunteers 7 Factors associated with higher log transformed S1-binding antibodies titers in hemodialysis patients included younger age, BMI under 30, serum albumin above 3.5gr/dl and reduced intravenous iron dose. In line with our findings, Grupper et al. also demonstrated a significant inverse correlation between older age and antibodies levels in the hemodialysis group as well as in the control group 8 . Nutritional status is a known risk factor for dampened antibody response to immunization in dialysis patients 5, 9 . Hypoalbuminemia as a marker of malnutrition and inflammatory state, has been also shown to correlate with diminished seroconversion in response to hepatitis B (HBV) vaccine 10, 11 . However, higher BMI, which is often associated with improved nutritional state and outcome in dialysis patients, was previously reported to corelate with inferior response to HBV vaccine 10, 12 . Both iron deficiency and iron overload are associated with impaired immune reactivity. Intravenous iron supplementation was found to be associated with reduced antibody response in our study, as well as in a previous study that found that intravenous iron blunted the humoral response to HBV vaccination 13 .

Our study has several limitations. First, correlation between antibody response to vaccine and protection against SARS-CoV-2 infection has not yet been proven. Nevertheless, evidence is accumulating to support antibody response as a potential correlate of disease protection.

Furthermore, we did not include neutralization antibodies and cellular immunity assays in our study. However, a strong correlation has been reported between anti-S antibody titers and neutralization antibody levels 7, 14, 15 .

In conclusion, in our cohort, high seropositivity rates above 90% were demonstrated among 122 hemodialysis and 23 PD patients following BNT162b2 vaccination, with few serious adverse events. Younger age, BMI under 30, normal albumin level and reduced intravenous iron dose were associated with elevated anti-S antibody titers in hemodialysis patients. These findings strongly support the efficacy of the BNT162b2 vaccination among dialysis patients.

BRZ reports a consulting fee from Fresenius Medicare and a payment for lecture from AstraZeneca plc. BZ reports a consulting fee from Fresenius Medicare. All remaining authors have nothing to disclose 

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

The urgent need to vaccinate dialysis patients against SARS-CoV-2: A call to action

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Safety and Efficacy of the BNT162b2 mRNA Covid-19

Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis CJASN

Vaccination and chronic kidney disease

Hepatitis B virus vaccine immune response and mortality in dialysis patients: a meta-analysis

Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: A systematic review and metaanalysis

Is there any survival advantage of obesity in Southern European haemodialysis patients? Nephrol Dial Transplant

Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Serum albumin (per gr/dL) 3